Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023759 · ClinicalTrials.gov registry record
Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)
A clinical trial, sponsored by Formula30A.
- Completed
- Registry status
- 30
- Enrollment target
NCT05023759 is a clinical trial that has completed, run by Formula30A. The registered enrollment target is 30 participants.
The verdict
NCT05023759 has completed, sponsored by Formula30A.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest. Cannabidiol (CBD) has shown promise as an effective treatment for anxiety-related symptoms while lacking the severity of adverse effects seen with other medications. Given the wide availability of products containing CBD on the market today, from tinctures to coffee additives, and the undetermined potential for drug-to-drug interactions, medical supervision of CBD intake and formulation-specific clinical research is necessary. Therefore this study aimed to observe the effects of a specific hemp-derived full spectrum CBD formula on anxiety-related symptoms in a group of volunteers. The investigators will examine the self-reported anxiety symptoms in relation to use of a specific CBD formulation (25mg solvent-free full spectrum CBD capsules) in a cohort of adults diagnosed with generalized anxiety disorder. This open-label, cohort study will be conducted at six clinic sites in the United States (including Puerto Rico) from June 2020 through October 2020. The six physicians recruited to participate in the study were each actively prescribing CBD in their practices and were actively caring for patients with anxiety symptoms. Anxiety levels will be measured in enrolled participants diagnosed with generalized anxiety disorder each week for a period of eight weeks using the Generalized Anxiety Disorder 7-Item Scale (GAD7). Participants will also be instructed to take a daily 25mg capsule of CBD. The investigators hypothesize that this formula, when carefully developed and administered by a healthcare professional, will significantly reduce anxiety symptoms.
Interventions
- DIETARY_SUPPLEMENT Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2020-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023759
The ClinicalTrials.gov registry entry for NCT05023759 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Formula30A, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules is the first listed.
NCT05023759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05023759 about?
NCT05023759 is a clinical study titled "Anxiety Symptoms in Relation to Use of Hemp-derived, Full Spectrum Cannabidiol (CBD)". Generalized anxiety disorder affects about 6.8 million adults in the United States, therefore its treatment is of major public health interest. Cannabidiol (CBD) has shown promise as an effective treatment for anxiety-related symptoms while lacking the severity of adverse effects seen with other med...
What is the current status of trial NCT05023759?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2020-06-01. Estimated completion is 2020-10-31.
What interventions are being tested in trial NCT05023759?
The interventions under investigation include: Formula30A Full Spectrum Hemp Cannabidiol 25mg Capsules (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05023759?
This trial is sponsored by Formula30A, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.